359 related articles for article (PubMed ID: 30377088)
1. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms.
Kanagal-Shamanna R; Hodge JC; Tucker T; Shetty S; Yenamandra A; Dixon-McIver A; Bryke C; Huxley E; Lennon PA; Raca G; Xu X; Jeffries S; Quintero-Rivera F; Greipp PT; Slovak ML; Iqbal MA; Fang M
Cancer Genet; 2018 Dec; 228-229():197-217. PubMed ID: 30377088
[TBL] [Abstract][Full Text] [Related]
2. Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group.
Xu X; Bryke C; Sukhanova M; Huxley E; Dash DP; Dixon-Mciver A; Fang M; Griepp PT; Hodge JC; Iqbal A; Jeffries S; Kanagal-Shamanna R; Quintero-Rivera F; Shetty S; Slovak ML; Yenamandra A; Lennon PA; Raca G
Cancer Genet; 2018 Dec; 228-229():218-235. PubMed ID: 30344013
[TBL] [Abstract][Full Text] [Related]
3. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
4. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
Ronaghy A; Yang RK; Khoury JD; Kanagal-Shamanna R
Curr Hematol Malig Rep; 2020 Jun; 15(3):194-202. PubMed ID: 32382988
[TBL] [Abstract][Full Text] [Related]
5. Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia.
Chun K; Wenger GD; Chaubey A; Dash DP; Kanagal-Shamanna R; Kantarci S; Kolhe R; Van Dyke DL; Wang L; Wolff DJ; Miron PM
Cancer Genet; 2018 Dec; 228-229():236-250. PubMed ID: 30554732
[TBL] [Abstract][Full Text] [Related]
6. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
7. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders.
Pugh TJ; Fink JM; Lu X; Mathew S; Murata-Collins J; Willem P; Fang M;
Cancer Genet; 2018 Dec; 228-229():184-196. PubMed ID: 30393007
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of previously cryptic copy number alterations and loss of heterozygosity in pediatric acute myeloid leukemia and myelodysplastic syndrome determined using combined array comparative genomic hybridization plus single-nucleotide polymorphism microarray analyses.
Koh KN; Lee JO; Seo EJ; Lee SW; Suh JK; Im HJ; Seo JJ
J Korean Med Sci; 2014 Jul; 29(7):926-33. PubMed ID: 25045224
[TBL] [Abstract][Full Text] [Related]
9. Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC).
Mikhail FM; Biegel JA; Cooley LD; Dubuc AM; Hirsch B; Horner VL; Newman S; Shao L; Wolff DJ; Raca G
Genet Med; 2019 Sep; 21(9):1903-1916. PubMed ID: 31138931
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP
Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, cross-platform clinical validation study of cancer cytogenomic arrays.
Li MM; Monzon FA; Biegel JA; Jobanputra V; Laffin JJ; Levy B; Leon A; Miron P; Rossi MR; Toruner G; Alvarez K; Doho G; Dougherty MJ; Hu X; Kash S; Streck D; Znoyko I; Hagenkord JM; Wolff DJ
Cancer Genet; 2015 Nov; 208(11):525-36. PubMed ID: 26454669
[TBL] [Abstract][Full Text] [Related]
12. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
13. Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome.
da Silva FB; Machado-Neto JA; Bertini VHLL; Velloso EDRP; Ratis CA; Calado RT; Simões BP; Rego EM; Traina F
J Clin Pathol; 2017 May; 70(5):435-442. PubMed ID: 27836923
[TBL] [Abstract][Full Text] [Related]
14. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
[TBL] [Abstract][Full Text] [Related]
16. Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes.
Qin Y; Zhang H; Feng L; Wei H; Wu Y; Jiang C; Xu Z; Zhu H; Liu T
Ann Med; 2022 Dec; 54(1):2627-2636. PubMed ID: 36148999
[TBL] [Abstract][Full Text] [Related]
17. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
[TBL] [Abstract][Full Text] [Related]
18. Significance of genome-wide analysis of copy number alterations and UPD in myelodysplastic syndromes using combined CGH - SNP arrays.
Ahmad A; Iqbal MA
Curr Med Chem; 2012; 19(22):3739-47. PubMed ID: 22680919
[TBL] [Abstract][Full Text] [Related]
19. Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup.
Liu YJ; Houldsworth J; Emmadi R; Dyer L; Wolff DJ
Cancer Genet; 2020 Jun; 244():40-54. PubMed ID: 32434132
[TBL] [Abstract][Full Text] [Related]
20. Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.
Larsson N; Lilljebjörn H; Lassen C; Johansson B; Fioretos T
Eur J Haematol; 2012 Feb; 88(2):136-43. PubMed ID: 21933280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]